AI PRICE FORECAST
ISRG Stock Forecast & AI Price Prediction
Intuitive Surgical · Healthcare · Medical Instruments & Supplies
ISRG live signal snapshot
Shares of ISRG were last at $449.53, down 0.11% on the day, trading 25.6% below its 52-week high of $603.88 and 36.8% above its 52-week low of $328.57. Our AI model's current call on ISRG is HOLD, with 70% confidence. The technical signals aren't aligned enough for a directional call yet. The short-term averages line up bullishly, and the price is holding above its 50-day line. Its one-month projection is about $430.27, a -4.3% move from the last price.
ISRG's 14-day RSI is 48.9 — a neutral zone, with no decisive edge for bulls or bears. The MACD indicator trails its signal line, with a histogram of -1.19 pointing to selling pressure. With the 50-day average at $414.76, 3.6% under the 200-day's $430.11, the longer-term trend structure is still negative.
30 Wall Street analysts covering ISRG put the average price target at $486.57 (range $324.00–$685.00), implying 8.2% upside from the current price. The current recommendation trend leans bullish: 26 Buy/Strong Buy ratings vs 2 Sell/Strong Sell (and 6 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive ISRG dashboard for numbers updated throughout today's session.
About Intuitive Surgical
Intuitive Surgical, Inc. (ISRG) is a medical instruments & supplies company in the healthcare sector, headquartered in Sunnyvale, CA, United States. Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It has a market value of about $155.8 billion and roughly 17,021 full-time employees. With a beta of 1.44, the stock has historically swung more than the overall market.
ISRG performance vs. the market
ISRG is down 20.6% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 22.0%, 33.5 points worse than the S&P 500. Its +6.5% move over the past month extends a +12.0% three-month run.
| Period | ISRG | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +6.5% | +11.4% | −2.3% |
| 3 months | +12.0% | +12.2% | −2.3% |
| Year to date | −20.6% | +22.1% | +11.4% |
| 1 year | −22.0% | +28.3% | +11.5% |
Intuitive Surgical financials at a glance
Intuitive Surgical's most recent quarter (ended Sep 30, 2026) brought in $3.0 billion of revenue and net income of $523 million (a 17.1% net margin). Revenue was up 21.7% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 54.4 on trailing earnings of $8.27 per share. Trailing free cash flow was $3.4 billion.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $3.0B | $523M |
| Jun 30, 2026 | $2.9B | $818M |
| Mar 31, 2026 | $2.8B | $822M |
| Dec 31, 2025 | $2.9B | $795M |
ISRG vs. its peers
ISRG's −20.6% this year ranks ahead of 0 of the 5 big healthcare names below. The strongest of the group this year is Merck & Co. (MRK, +39.8%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Intuitive Surgical (ISRG) | $449.53 | −20.6% | 54.4 | HOLD |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| UnitedHealth Group (UNH) | $402.94 | +22.1% | 23.0 | HOLD |
ISRG stock: common questions
What is the ISRG stock price target?
30 Wall Street analysts put the average 12-month target at $486.57, in a range of $324.00–$685.00, versus a recent price of $449.53. Stock Pulse 247's model projects about $430.27 over the next month.
Is ISRG a buy right now?
Our AI model currently rates ISRG a HOLD at 70% confidence. Among analysts, 26 rate it Buy or Strong Buy, 6 Hold and 2 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has ISRG stock performed this year?
ISRG is down 20.6% so far in 2026, behind the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has lost 22.0%, 33.5 points worse than the S&P 500. Its +6.5% move over the past month extends a +12.0% three-month run.
What is ISRG's 52-week high and low?
ISRG has traded between $328.57 and $603.88 over the past 52 weeks; at $449.53 it is 25.6% below its 52-week high of $603.88 and 36.8% above its 52-week low of $328.57.
What sector is ISRG in, and who are its peers?
ISRG is in the healthcare sector (medical instruments & supplies). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK).
How accurate is the ISRG forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines ISRG's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.